WO2010115202A3 - Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna - Google Patents

Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna Download PDF

Info

Publication number
WO2010115202A3
WO2010115202A3 PCT/US2010/029986 US2010029986W WO2010115202A3 WO 2010115202 A3 WO2010115202 A3 WO 2010115202A3 US 2010029986 W US2010029986 W US 2010029986W WO 2010115202 A3 WO2010115202 A3 WO 2010115202A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
kras
methods
stranded rna
specific inhibition
Prior art date
Application number
PCT/US2010/029986
Other languages
French (fr)
Other versions
WO2010115202A2 (en
Inventor
Bob D. Brown
Original Assignee
Dicerna Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dicerna Pharmaceuticals, Inc. filed Critical Dicerna Pharmaceuticals, Inc.
Publication of WO2010115202A2 publication Critical patent/WO2010115202A2/en
Publication of WO2010115202A3 publication Critical patent/WO2010115202A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention relates to compounds, compositions, and methods useful for reducing KRAS target RNA and protein levels via use of blunt-ended Dicer substrate siRNA (DsiRNA) agents.
PCT/US2010/029986 2009-04-03 2010-04-05 Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna WO2010115202A2 (en)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US16655909P 2009-04-03 2009-04-03
US16657809P 2009-04-03 2009-04-03
US61/166,559 2009-04-03
US61/166,578 2009-04-03
US17427909P 2009-04-30 2009-04-30
US17430609P 2009-04-30 2009-04-30
US61/174,306 2009-04-30
US61/174,279 2009-04-30
US25781009P 2009-11-03 2009-11-03
US25782009P 2009-11-03 2009-11-03
US61/257,820 2009-11-03
US61/257,810 2009-11-03

Publications (2)

Publication Number Publication Date
WO2010115202A2 WO2010115202A2 (en) 2010-10-07
WO2010115202A3 true WO2010115202A3 (en) 2010-12-09

Family

ID=42828982

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/029986 WO2010115202A2 (en) 2009-04-03 2010-04-05 Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna

Country Status (1)

Country Link
WO (1) WO2010115202A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2768958T3 (en) 2011-10-18 2019-09-16 Dicerna Pharmaceuticals Inc CATIONIC AMINLIPIDS AND APPLICATIONS THEREOF
KR20150004414A (en) * 2012-05-02 2015-01-12 노파르티스 아게 Organic compositions to treat kras-related diseases
KR102205278B1 (en) 2013-03-14 2021-01-22 다이서나 파마수이티컬, 인크. Process for formulating an anionic agent
BR112018004620A2 (en) * 2015-09-24 2018-09-25 Ionis Pharmaceuticals, Inc. kras expression modulators
JP2019535839A (en) 2016-11-29 2019-12-12 ピュアテック ヘルス エルエルシー Exosomes for the delivery of therapeutic agents
US10626165B2 (en) 2016-12-14 2020-04-21 Janssen Biotech, Inc. CD8a-binding fibronectin type III domains
WO2018111976A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Pd-l1 binding fibronectin type iii domains
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
WO2018172546A1 (en) * 2017-03-24 2018-09-27 Rigontec Gmbh Method for designing rig-i ligands
BR112020016228A2 (en) * 2018-02-12 2020-12-08 Codiak Biosciences, Inc. METHODS AND COMPOSITIONS FOR POLARIZATION OF MACROPHAGES
JP2022527108A (en) * 2019-03-29 2022-05-30 ディセルナ ファーマシューティカルズ インコーポレイテッド Compositions and Methods for the Treatment of KRAS-Related Diseases or Disorders
WO2021076574A2 (en) * 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
JP2022551204A (en) 2019-10-14 2022-12-07 アロ・バイオセラピューティクス・カンパニー CD71-binding fibronectin type III domain
JP2024516168A (en) * 2021-04-22 2024-04-12 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Compositions and methods for treating cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020076696A1 (en) * 1996-11-08 2002-06-20 Haruma Kawaguchi Method for determination of specific nucleic acid sequence and a reagent therefor
US20040063111A1 (en) * 2000-08-25 2004-04-01 Toshikazu Shiba Method for protecting personal information
US20070088152A1 (en) * 2002-11-14 2007-04-19 Dharmacon Inc. siRNA targeting KRAS
US20070254850A1 (en) * 2002-10-30 2007-11-01 Judy Lieberman Methods for Treating and Preventing Apoptosis-Related Diseases Using Rna Interfering Agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020076696A1 (en) * 1996-11-08 2002-06-20 Haruma Kawaguchi Method for determination of specific nucleic acid sequence and a reagent therefor
US20040063111A1 (en) * 2000-08-25 2004-04-01 Toshikazu Shiba Method for protecting personal information
US20070254850A1 (en) * 2002-10-30 2007-11-01 Judy Lieberman Methods for Treating and Preventing Apoptosis-Related Diseases Using Rna Interfering Agents
US20070088152A1 (en) * 2002-11-14 2007-04-19 Dharmacon Inc. siRNA targeting KRAS

Also Published As

Publication number Publication date
WO2010115202A2 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
WO2010115206A3 (en) Methods and compositions for the specific inhibition of kras by asymmetric double-stranded rna
WO2010115202A3 (en) Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna
WO2012006241A3 (en) Methods and compositions for the specific inhibition of androgen receptor by double-stranded rna
WO2012006243A3 (en) Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna
WO2015003113A3 (en) Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded rna
WO2010141726A3 (en) Peptide dicer substrate agents and methods for their specific inhibition of gene expression
CA2792561C (en) Compositions and methods for inhibiting expression of cd274/pd-l1 gene
MX2018013216A (en) Compositions and methods for inhibiting expression of tmprss6 gene.
EA201792626A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING TRANSTIRETIN EXPRESSION
WO2009129465A3 (en) Compositions and methods for inhibiting expression of xbp-1 gene
WO2008152131A3 (en) Rnai inhibition of alpha-enac expression
WO2012135736A3 (en) Modulation of signal transducer and activator of transcription 3 (stat3) expression
WO2009076400A3 (en) Compositions and methods for inhibiting expression of factor vii gene
WO2009111658A3 (en) Compositions and methods for inhibiting expression of eg5 and vegf genes
WO2012153193A3 (en) Protein-active agent conjugates and method for preparing the same
WO2010045384A3 (en) Short hairpin rnas for inhibition of gene expression
EA201190144A1 (en) ISOTHIAOSOLYLOXYPHENYLAMIDINES AND THEIR APPLICATION AS FUNGICIDES
WO2012145582A3 (en) Methods and compositions for the specific inhibitions of egfr by double-stranded rna
WO2016183009A3 (en) Methods and compositions for the specific inhibition of antithrombin 3 (at3) by double-stranded rna
WO2014093746A3 (en) Methods and compositions for the specific inhibition of ckap5 by double-stranded rna
WO2012027713A3 (en) Compositions and methods for inhibition of snca
WO2010028054A8 (en) Compositions and methods for inhibiting expression of mutant egfr gene
WO2011160052A3 (en) Methods and compositions for sequence specific rna endonucleases
WO2013068850A3 (en) PROCESS FOR THE PREPARATION OF β-C-ARYL GLUCOSIDES
WO2007106915A3 (en) Antibodies to egfl7 and methods for their use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10759545

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10759545

Country of ref document: EP

Kind code of ref document: A2